<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="1603">
  <stage>Registered</stage>
  <submitdate>25/06/2007</submitdate>
  <approvaldate>25/06/2007</approvaldate>
  <nctid>NCT00493116</nctid>
  <trial_identification>
    <studytitle>Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta</studytitle>
    <scientifictitle>A Multi-Centre, Open Label Study to Investigate the Recovery of IFN-beta Efficacy in Relapsing-Remitting Multiple Sclerosis Patients With Neutralising IFN-beta Antibodies and Reduced Bioavailability</scientifictitle>
    <utrn />
    <trialacronym>RENeu</trialacronym>
    <secondaryid>AUS-8001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Relapsing-Remitting Multiple Sclerosis</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Interferon-beta-1a
Treatment: drugs - methylprednisolone

Experimental: 1 - 


Treatment: drugs: Interferon-beta-1a
dosage and frequency as per Biogen Idec protocol

Treatment: drugs: methylprednisolone
dosage and frequency as per Biogen Idec protocol

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>return of bioavailability of AVONEX (interferon-beta-1a) as measured by induction of MxA mRNA</outcome>
      <timepoint>screening and every 3 months from month 6 to month 27</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of patients becoming neutralizing antibody negative</outcome>
      <timepoint>screening and every 3 months from month 3 to month 27</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of patients becoming neutralizing antibody positive after treatment with AVONEX</outcome>
      <timepoint>at baseline and every three months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of patents relapse free</outcome>
      <timepoint>months 6, 12, 18 and 24</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>total relapses</outcome>
      <timepoint>27 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>proportion of patients with an increase in EDSS of 1 point</outcome>
      <timepoint>screening, 3, 9, 15, 21, and 27 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Brain atrophy and cumulative number of enlarging T2 lesions on MRI</outcome>
      <timepoint>months 0, 12, and 27</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Must have been receiving interferon-beta-1a or interferon-beta-1b for a minimum of 12
             consecutive months prior to enrollment

          -  Relapsing-Remitting Multiple Sclerosis according to Poser or McDonald criteria

          -  EDSS score of 6 or less

          -  NAB titre &gt;or equal to 20 via CPE assay or &gt;or equal to 100 via MxA Protein assay
             measured at least 24 hours after last interferon-beta injection on two consecutive
             tests at least 3 months apart

          -  Reduced bioavailability (relative expression of MxA mRNA/GAPDH</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of severe allergic or anaphylactic reaction to human albumin, to any
             interferon, Methylprednisolone or to any other component of study drugs

          -  Clinically significant systemic illness

          -  History of poorly controlled hypertension, diabetes, or osteoporosis

          -  History of uncontrolled seizures within 3 months of enrollment

          -  History of Depression or suicidal ideation within 3 months of enrollment

          -  Serious local infection (abscess or cellulitis) or systemic infection within 8 weeks
             of study

          -  abnormal screening blood tests</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <hospital>Coordinating Research Site - NSW</hospital>
    <postcode> - NSW</postcode>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Hamilton</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Biogen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study is to find out if Interferon-beta (IFN-beta) can recover its effectiveness after a
      washout period in patients with Multiple Sclerosis who have previously developed neutralizing
      antibodies to Interferon-Beta</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00493116</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>